TY - JOUR
T1 - Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: A randomized crossover trial
AU - Verster, Joris C.
AU - Bekker, Evelijne M.
AU - de Roos, Marlise
AU - Minova, Anita
AU - Eijken, Erik J. E.
AU - Kooij, J. J. Sandra
AU - Buitelaar, Jan K.
AU - Kenemans, J. Leon
AU - Verbaten, Marinus N.
AU - Olivier, Berend
AU - Volkerts, Edmund R.
PY - 2008
Y1 - 2008
N2 - Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10-30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8-3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance. © 2008 British Association for Psychopharmacology.
AB - Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10-30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8-3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance. © 2008 British Association for Psychopharmacology.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=45349088522&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/18308788
U2 - https://doi.org/10.1177/0269881107082946
DO - https://doi.org/10.1177/0269881107082946
M3 - Article
C2 - 18308788
SN - 0269-8811
VL - 22
SP - 230
EP - 237
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 3
ER -